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Background: Osteoarthritis (OA) is the most common type of arthritis, causing significant joint pain and disability. It
is already a major cause of healthcare expenditure and its incidence will further increase with the ageing
population. Current treatments for OA have major limitations and new analgesic treatments are needed. Synovitis is
prevalent in OA and is associated with pain. Hydroxychloroquine is used in routine practice for treating synovitis in
inflammatory arthritides, such as rheumatoid arthritis. We propose that treating patients with symptomatic hand OA
with hydroxychloroquine will be a practical and safe treatment to reduce synovitis and pain.
Methods/design: HERO is an investigator-initiated, multicentre, randomized, double-blind, placebo-controlled trial.
A total of 252 subjects with symptomatic hand OA will be recruited across primary and secondary care sites in the
UK and randomized on a 1:1 basis to active treatment or placebo for 12 months. Daily medication dose will range
from 200 to 400 mg according to ideal body weight. The primary endpoint is change in average hand pain during
the previous two weeks (measured on a numerical rating scale (NRS)) between baseline and six months. Secondary
endpoints include other self-reported pain, function and quality-of-life measures and radiographic structural change
at 12 months. A health economics analysis will also be performed. An ultrasound substudy will be conducted to
examine baseline levels of synovitis. Linear and logistic regression will be used to compare changes between
groups using univariable and multivariable modelling analyses. All analyses will be conducted on an intention-to
-treat basis.
Discussion: The HERO trial is designed to examine whether hydroxychloroquine is an effective analgesic treatment
for OA and whether it provides any long-term structural benefit. The ultrasound substudy will address whether
baseline synovitis is a predictor of therapeutic response. This will potentially provide a new treatment for OA, which
could be of particular use in the primary care setting.
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Osteoarthritis (OA) is an increasingly common problem
in ageing Western societies, affecting an estimated
8.5 million people in the UK and causing both an enor-
mous burden to health systems and considerable pain
and disability to affected individuals [1,2]. Although
radiographic hand OA (RHOA) is recognized as being
highly prevalent in the older population, with 60 to 70%
of people over the age of 55 estimated to have RHOA
[3], there is a common misconception that symptomatic
hand OA is not a prevalent disease. However population
data suggests symptomatic hand OA to be more preva-
lent than symptomatic knee OA [4], affecting 8% of
people aged 60 or over [5] and 26% of women and 13%
of men aged 70 or over [6]. The notable paucity of pub-
lished clinical research examining the clinical impact,
epidemiology and therapy of hand OA, as compared
with hip and knee OA [7], may be attributed to patients
with symptomatic hand OA failing to seek medical care
[8], perhaps because of both their own perception of a
lack of treatment options and reinforcement of this view
by medical practitioners [9].
The most commonly involved joints in symptomatic
hand OA are the distal and proximal interphalangeal
joints, followed by the base of the thumb [6]. Significant
difficulties with daily tasks, such as gripping, writing,
carrying heavy items and picking up small objects, have
been reported by patients with symptomatic hand OA
[6], with 50% reporting problems in wringing out wash-
cloths and opening jars and a 60% reduction in grip
strength [10]. Moreover, the onset of hand OA signifi-
cantly impacts on the deterioration of global physical
functioning, irrespective of concurrent lower-limb joint
pain [11]. Symptomatic hand OA, therefore, represents a
considerable economic, clinical and social burden.
Current guidelines for hand OA treatment, such as
those from the UK National Institute for Health and
Clinical Excellence (NICE) and the European League
against Rheumatism (EULAR), recommend topical treat-
ments, such as NSAID gel and capsaicin cream, oral an-
algesia (including paracetamol and oral NSAIDs) and
nonpharmacological therapy [12,13]. However, these
treatments are precluded by comorbidities and often re-
stricted in their duration by degree of efficacy and con-
siderable associated toxicities. Moreover, since the
majority of data guiding treatment for OA is derived
from studies on the knee, more studies on therapies for
symptomatic hand OA are required.
Although traditionally considered a disease of articular
cartilage, modern imaging studies have vastly improved
our understanding of the complex inter-relationship of
the tissues involved in the pathophysiology of OA, and
clearly demonstrate OA to be a disease of the whole
joint, involving subchondral bone changes, osteophyteformation and synovial inflammation [14,15]. In knee
OA, a change in MRI-detected synovitis score is signifi-
cantly correlated with a change in knee-pain score (P <
0.001, r = 0.21) [16,17], while 82% of painful OA hand
joints had ultrasound-detected synovitis, with painful
hand joints more likely to have synovitis than nonpainful
hand joints (P < 0.001) [18]. Moreover, 86% of patients
with American College of Rheumatology (ACR) hand
OA and erosive changes seen on X-ray displayed
ultrasound-detected synovial thickening and 82% an in-
creased power Doppler signal [19]. Patients with higher
levels of ultrasound-detected synovitis at baseline have
also been shown to have a better response to intramus-
cular steroids, which are thought to work by reducing
synovitis [20]. Taken together, these studies suggest that
treatments to target synovitis may be effective in redu-
cing pain in OA.
Hydroxychloroquine has been successfully used for
many years in the treatment of inflammatory arthritides,
such as rheumatoid arthritis (RA) and systemic lupus
erythematosus, and less commonly in the serone-
gative spondyloarthropathies [21,22]. Placebo-controlled
trials in RA have demonstrated significant efficacy of
hydroxychloroquine, both as a monotherapy and in
combination with other RA drugs, and - due to its excel-
lent safety profile it remains a popular therapy for RA.
Although hydroxychloroquine’s mechanism of action in
RA is poorly understood, it is presumed to be associated
with an anti-synovial activity.
Although hydroxychloroquine has been used on an an-
ecdotal basis for the treatment of OA, there have been
few studies to assess its efficacy and these studies have
contained only small numbers of patients. A summary of
these studies is presented in Figure 1 and Table 1. The
small numbers of patients, different inclusion criteria
and outcome measures used in these trials allow limited
conclusions to be drawn. However, the reported im-
provement in patient symptoms compared with control
arms in the majority of these studies suggests a need
for a properly designed and well-powered trial to be
performed.
We propose that treating patients with symptomatic
hand OA with hydroxychloroquine will be a practical and
safe treatment to reduce synovitis and therefore reduce
pain. We believe that the preliminary data from the handful
of small studies previously conducted and anecdotal evi-
dence of hydroxychloroquine efficacy in hand OA strongly
support the need for a well-designed, adequately powered,
randomized placebo-controlled trial to examine fully the
potential use of hydroxychloroquine as a treatment for
OA. The hydroxychloroquine effectiveness in reducing
symptoms of hand osteoarthritis (HERO) trial was
designed to this end. The protocol of the HERO trial
is outlined in this paper.
n=265 
Duplicates (n=78) 
Embase: 259 
Pubmed: 42 
Not meeting selection crit eria: Review articles 
(n=124); case reports (n=1); editorials (n=4); surveys 
(n=9); audits (n=1); notes (n=3); conference 
proceedings (n=5); studies ex-vivo (n=47); articles 
pertaining to other arthropathies (n=43); not relevant n=8 
Figure 1 Overview of systematic review of hydroxychloroquine use in osteoarthritis. Databases: PubMed, MEDLINE and Embase. Search
terms: MeSH headings #1 ‘osteoarthritis’ and #2 ‘hydroxychloroquine’ or ‘chloroquine’. Limits: Humans.
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Trial development
The trial was designed with key stakeholders including
rheumatologists with experience of treating OA, general
practitioners with a special interest in musculoskeletal
disease, methodologists and users with experience of
hand OA.
Trial objectives
The trial will aim to address the following questions:
1. Is hydroxychloroquine an effective analgesic
treatment for OA?
2. What is the time course for symptomatic relief with
hydroxychloroquine?
3. Does hydroxychloroquine treatment provide any
long-term structural benefit?
The ultrasound substudy will address whether baseline
synovitis is a predictor of therapeutic response.
Population
All adults with symptomatic, radiographic hand osteo-
arthritis and inadequate response or toxicity to their
existing medication (to include paracetamol, oral NSAID
or opioid).
Intervention
Hydroxychloroquine is a 4-aminoquinoline anti-malarial
drug that, because of its weak diprotic base properties, is
able to pass through lipid cell membranes and preferen-
tially accumulate in acidic cytoplasmic vesicles within
macrophages and antigen-presenting cells. In vitro stu-
dies demonstrate that by increasing vesicle pH,
hydroxychloroquine is able to modulate the antigen-
processing activity of these cells, resulting in down-
regulation of the immune response [31]. Moreover,
hydroxychloroquine is able to block T-cell activation
[32] and reduce the release of various cytokines, inclu-
ding interleukin (IL)-1, IL-6, tumour necrosis factor andIL-1β-induced nitric oxide, that have been demonstrated
to be involved in OA inflammation and cartilage dege-
neration [33-35]. It has also significantly reduced matrix
metalloprotease levels in a rat calcium pyrophosphate
disease model [36]. Inhibition of cytokine production
and reduction of T-cell activity is the probable mecha-
nism underlying hydroxychloroquine’s efficacy in RA.
The relevance of these inflammatory pathways to OA
pathology [21,22,31,32], coupled with the evidence that
synovitis is closely correlated with pain in the OA joint,
suggests that hydroxychloroquine might also be an effi-
cacious analgesic agent for the treatment of OA.
Outcome measures
The HERO trial will examine a range of clinical, imaging
and quality-of-life and economic outcomes, in line with
the objectives listed.
Clinical outcome measures
The primary endpoint of the study will be change in
‘average overall hand pain severity over the previous two
weeks’ (as graded on a 0 to 10 numerical rating scale)
between baseline and six months. Secondary outcome
measures are outlined in Table 2.
Imaging outcome measure
Structural progression between baseline and 12 months
will be assessed by calculating change in the Kallman
score [44].
Quality-of-life and health economic outcome measures
Utility will be measured using the EuroQol (EQ-5D-5L),
deriving quality-adjusted life years (QALYs) for each par-
ticipant. Disease-specific quality-of-life (QoL) measures
are listed in Table 2.
Study design
HERO was designed as an investigator-initiated multicentre,
randomized, double-blindplacebo-controlled trial to com-
pare the analgesic efficacy of hydroxychloroquine in painful
Table 1 Systematic review of hydroxychloroquine use in osteoarthritis
Reference n Site Treatment Outcome
[23] 8 Erosive hand OA
unresponsive to NSAIDs
200 mg HCQ 6/8 noted improvement in pain, reduced synovitis and reduced
morning stiffness
Response time 7/52 to 7/12. No adverse effects
[24] 15 Hand OA Placebo-controlled HCQ Improvement in clinical symptoms at 12 months (Ritchie index)
[25] 7 Erosive hand OA 200 to 400 mg HCG Improvement in 7/7 patients noted
[26] 15 Hand and knee OA HCQ 6/12 13/15 patients achieved good therapeutic response after 6 months
[27] 29 Knee OA 400 mg HCQ 4/12,
placebo-controlled
No difference in WOMAC pain (P = 0.551), stiffness (P = 0.512) or function
(P = 0.293); no difference on VAS (P = 0.461) or Lequesne (P = 0.803) scales
[28] 88 Nodal OA of the hands HCQ 200 mg/bid, ACM 1.3
gm/tid or placebo 6/12
No significant difference between hydroxychloroquine, acetaminophen
or placebo in mean number of tender joints at 24 weeks
[29] 8 Erosive or inflammatory OA HCQ 200 to 400 mg Clinical improvement in 5/8 patients, 3 patients discontinued (1 due to
unresponsiveness, 2 due to side-effects)
[30] Intra-articular chloroquine in RA and OA of knee joint
No abstract available
ACM, acetaminophen; HCQ, hydroxychloroquine; MeSH, medical subject headings; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster
Universities Index of OA.
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hydroxychloroquine or placebo. Given the pragmatic nature
of the trial, participants in both treatment arms will be
allowed drugs licensed for use in pain management of OA;
with drugs and doses determined by clinicians for individual
participants. Treatment will be for 12 months.
Sample size
The sample size for the HERO trial was estimated based
on the primary outcome of change in hand pain, be-
tween baseline and 6 months, as measured on a 0-to-10
NRS. Mean baseline pain scores of 5.06 (standard devi-
ation (SD), 2.079) and 5.50 (SD 2.5) from previous hand
osteoarthritis interventional studies were used to esti-
mate the expected mean (SD) pain scores for this study
[45].
The HERO trial is powered to detect an effect size of
0.4, as this is equivalent to the reported effect size of
NSAIDs as a treatment for hand OA obtained from two
large studies with a total of 654 participants [46,47].
With the estimated mean pain numerical rating scores
and SD, in this instance an effect size of 0.4 is equivalent
to a 15% change on the pain scale, which lies within the
minimal clinically important difference for change in
pain in a randomized trial (10 to 20%) [48].
To detect an effect size of 0.4, with 80% power and 5%
significance, 101 participants would be required per arm.
Allowing for a conservative 20% dropout, a total of 252
participants will therefore need to be recruited into the
study.
Statistical analysis
All analyses will be conducted on an intention-
to-treat basis, including all randomized participants inthe groups to which they were randomized. Baseline
data will be reported descriptively. No formal statistical
comparisons of baseline data will be undertaken. The
flow of participants through the trial will be presented in
a CONSORT diagram. The numbers of participants
withdrawing from treatment will be summarized by
treatment group.
The primary analysis will estimate the difference in
‘average overall hand pain severity over the previous
2 weeks’ at 6 months between the hydroxychloroquine
and placebo groups using a linear mixed model (linear
regression for correlated data) adjusting for the baseline
measure and other important covariates (for example,
chronic drug use).
The secondary analyses will estimate treatment diffe-
rences at 3 months and 12 months in the same linear
mixed model. Other continuous secondary outcomes
measured longitudinally will be analyzed using the same
methods as those employed for the primary outcome,
adjusting for the same covariates as the primary analysis.
The ordinal secondary outcomes, measured longitudi-
nally, will be assumed to be continuous and analyzed
using the methods described for the primary analysis.
Point estimates and their 95% confidence intervals will
be presented.
All secondary outcomes will be described descriptively
(mean, SD, median, minimum and maximum for con-
tinuous data and counts and percentages for categorical
data). The SF-12 will be summarized for all components.
For each outcome measure the number of nonres-
ponders will be calculated for each treatment group and
response rates compared. Appropriate sensitivity ana-
lyses will be used to examine the effects of missing data
on outcomes.
Table 2 Outcome measures and timetable
Month(s)
0 3 6 12
Primary outcome
Average overall hand pain severity over the previous 2 weeks (0 to 10 NRS) ✓ ✓ ✓ ✓
Secondary outcomes
Imaging assessments
• Bilateral hand X-ray ✓ ✓
• Ultrasound synovitis score ✓
Clinical assessments
• Grip strength ✓ ✓ ✓
• Joint count ✓ ✓ ✓
Self-reported questionnaires
• AUSCAN [37,38] (pain, stiffness and function) – five-point Likert scale ✓ ✓ ✓ ✓
• 11-point NRS and VAS scales [39] for: ✓ ✓ ✓ ✓
°Average overall hand pain severity / pain in the most painful joint over the past 2 weeks / 2 days
• NRS scales for: ✓ ✓ ✓ ✓
°Global disease activity / average thumb pain / average pain in other joints over the past 2days
°Severity rating of participant nominated main functional problem over the past 2 days
°Satisfaction with hand function over the past 2 days
°Hand pain, aching, or stiffness over the past month (no days to all days
• Globala improvement in hand problem/hand pain/ability to use hands ✓ ✓ ✓
• Pain elsewhere (pain manikin) ✓
• Duration of hand pain over the past 12 months (<7 days, 1 to 4 weeks, >1 month, <3 months, >3 months) ✓✓
• Onset of hand pain (last 12 months, 1 to 5 years, 5 to 10 years, 10 years or more) ✓
• Quality of life: SF12v2 and OAQoL [40] ✓ ✓ ✓
• EuroQol EQ-5D [41,42] ✓ ✓ ✓
• Depression and anxiety: HADS [43] ✓ ✓ ✓
Demographics and medical history ✓
Concomitant medicationb ✓ ✓ ✓ ✓
Adverse eventsb ✓ ✓ ✓
aA six-point Likert scale: completely better, much better, better, no change, worse, much worse. bAlso recorded at 1 month and 9 months. AUSCAN, Australian
Canadian osteoarthritis hand index; HADS, Hospital Anxiety and Depression Scale; NRS, numerical rating scale; OAQoL, Osteoarthritis Quality of Life Scale; VAS,
visual analogue scale.
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Health economics evaluation will be carried out to deter-
mine the cost effectiveness of using hydroxychloroquine
(the intervention) as part of a multi-drug regimen. The
intention-to-treat population will be used for all analyses,
with resource-use data collected from a National Health
Service (NHS) perspective. Medication use will be esti-
mated from the drug-history summary collected during
the trial. Health-service use will be measured using a pa-
tient health-services utilization questionnaire developed
for the HERO trial. Utility will be measured using the
EuroQol (EQ-5D-5L), deriving QALYs for each partici-
pant. Data on the cost and utility measures will be col-
lected at the same time points as for clinical outcomes.
Unit costs of medications will be taken from the BritishNational Formulary. Health-service use cost will be de-
rived from the annual NHS reference cost summary, iden-
tifying relevant healthcare resource group codes. Future
costs and outcomes will not be discounted, as follow-up
in the HERO trial is for 12 months.
The main analysis will be a within-trial analysis. A cost-
effectiveness analysis using the primary outcome in the
HERO trial, that is cost per unit of reduction in pain score
(as measured on a NRS) and cost-utility analysis deriving
cost per QALY saved will be conducted. For each analysis,
the following summary measures will be estimated:
1. Ratio measure: incremental cost-effectiveness ratio
obtained by dividing the incremental cost by the
incremental health benefit.
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based on pre-specified thresholds.
3. Probability measure: a cost-effectiveness acceptability
curve will be constructed.
Multiple imputation methods will be used to handle
missing data, where needed.
Trial procedures
Ethical approval for the study has been granted by the
Leeds East Research Ethics Committee (reference number
12/YH/0151). Informed written consent will be obtained
from all participants.
Participant recruitment
A total of 252 subjects with symptomatic hand OA will be
recruited and randomly allocated to either the treatment
or placebo control group. Recruitment methods will in-
clude advertisements through the local media and com-
munity groups, invitations to previous study participants
who have given their consent to be contacted regarding
future research projects and liaisons with musculoskeletal
physicians, general practitioners and allied health
professionals.
Informed consent and participant confidentiality
Informed consent will be obtained before patients are
screened for participation in the HERO trial. The right of
the patient to refuse consent without giving reasons will
be respected. Further, the patient will remain free to with-
draw from the study at any time without giving reasons
and without prejudicing any further treatment. The writ-
ten consent will be obtained by an appropriately delegated
clinician who is, by education and experience, qualified
to do so, and who has signed and dated the staff
authorization and delegation log. The process of obtaining
written consent will be clearly documented in the patient’s
medical notes. Patient confidentiality will be guaranteed at
all times, in line with the requirements of the Data Protec-
tion Act and NHS regulations.
Eligibility criteria
Participants must meet the inclusion and exclusion
criteria (Table 3) in order to participate. These will be
assessed at the screening visit (Figure 2). Potential partici-
pants who are deemed ineligible at screening will be
allowed a second screening visit if the reason for ineligibi-
lity is a temporary status (for example, recent steroid
injection; Table 3).
Treatment assignment and allocation concealment
Identical hydroxychloroquine and placebo capsules will be
produced to ensure allocation concealment. Upon produc-
tion, study medication will be packed into numberedbottles according to a randomization schedule. This will
be prepared by the contract manufacturer using a com-
puterized random number generator, thereby guarantee-
ing full allocation concealment. Study medication will be
issued in numerical order by the pharmacy. Participants in
each site will be randomly assigned to the intervention
arm or the placebo arm in a ratio of 1:1 and the
randomization will be double-blind. Dosage will be deter-
mined as per the schedule in Table 4.
Blinding
Investigators and participants will remain blinded
throughout the trial. Emergency unblinding will be
allowed in limited situations that impact on the safety of
study participants. Code-break envelopes for the full
randomization schedule will be maintained by the Leeds
General Infirmary pharmacy, and pharmacies at other
sites will hold code-break envelopes for their respective
participants.
Concomitant medications
Investigators will be responsible for the overall manage-
ment of a participant’s medication, and will ask participants
to avoid changing their analgesic or anti-inflammatory
medication for the duration of the trial. However, if a par-
ticipant is experiencing increased pain and requires an
increase in the dose of analgesics then the use of paraceta-
mol, topical or oral NSAIDs or opioids, or a combination
of these, will be permitted, but the reason for the dose
increase, and the dose used, will be documented. Chronic
NSAID and opioid use (most days in the last three months)
will be included as a covariate in the analysis. Additionally,
the following restrictions will apply throughout participant
follow-up:
1. Participants will be asked not to use any form of
steroids (oral, IV, IA or IM) during the trial period.
Any participant requiring oral corticosteroids for any
problem will be recorded as a protocol violator. A
single articular injection of corticosteroid will be
allowed in nonhand joints after the first 6-month
phase of the study.
2. Participants will be permitted to continue current
use of chondroitin and glucosamine, provided their
current dose has been stable for at least four months;
however chondroitin or glucosamine therapy will not
be commenced during the duration of the trial.
3. Participants will be asked not to start any new
nonpharmacological therapies for their hand OA,
including physiotherapy and hand splinting.
Data collection
All data collection will be done on standardized case re-
port forms, which will be completed by site staff, verified
Table 3 Eligibility criteria
Inclusion criteria Exclusion criteria
Patient-reported inadequate response or toxicity to existing medication
(to include paracetamol, oral NSAID or opioid)*
Presence of inflammatory arthritis (for example, gout, reactive arthritis, RA,
psoriatic arthritis, seronegative spondylarthropathy, Lyme disease)
Evidence of plaque psoriasisModerately severe symptoms (≥4/10 on a 0 to 10 VAS) at screening
Symptoms for more than half of days in the last 3 months OA of the 1st CMC joint and no symptomatic OA in other hand joints
Oral, IM, IA or IV steroids during the last 2 months*
Fulfil the American College of Rheumatology criteria for OA Any new hand OA treatment in the previous 2 months, including
physiotherapy and provision of new hand splint*
Radiograph of the hands in the past 5 years with changes consistent
with OA
Planned hand surgery in the next 6 months
No change in the average weekly dose of analgesics (including NSAIDs)
for at least 4 weeks*
Sensitivity, anaphylaxis or allergy to hydroxychloroquine or any other 4-
aminoquinoline compound
Unexplained visual impairment that is not corrected by glasses or
presence of any eye problems
Has used chondroitin or glucosamine for at least 4 months with no
change to the average weekly dose, is not using or is willing to stop
using if recently started*
Pregnant or lactating
Use of any investigational (unlicensed) drug within 1 month prior to
screening or within five half-lives of the investigational agent, whichever
is longer*
Evidence of serious uncontrolled concomitant medical condition,
including cardiovascular, nervous system, pulmonary, renal, hepatic,
endocrine, GI disease or epilepsy, which in the opinion of the investigator
makes them unsuitable for the study
Be able to adhere to the study visit schedule and other protocol
requirements
Capable of giving informed consent, which must be obtained prior to
any screening procedures
Uncontrolled disease states, such as moderate or severe asthma or
inflammatory bowel disease, where flares are commonly treated with oral
or parenteral corticosteroids
Melanoma or nonskin cancer in the past 3 years*
IA hyaluronans to the hand joints within the last 6/12*
Intolerance to lactose
Significant haematological or biochemical abnormality
Haemoglobin ≤ 8.5 g/dl
White cell count ≤ 3.5 × 109/l
Neutrophils ≤ 1.5 × 109/l
Platelets ≤ 100 × 109/l
ALT >2 times ULN for the laboratory conducting the test
Creatinine >1.5 times ULN for the laboratory conducting the test
*Criteria for which participants may be rescreened if they are ineligible at the initial screening visit. CMC, carpometacarpal; IA, intra-articular; IM, intramuscular; IV,
intravenous; RA, rheumatoid arthritis; ULN, upper limit of normal; VAS, visual analogue scale.
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trials unit for data entry. Study sites will also return a
patient nonidentifiable participant log and study drug
dispensing log to the clinical trials unit. The specific
tools used to capture each data element are further de-
tailed next and in Table 2.
Physical examination and vital signs
Vital signs, height and weight will be performed at
screening. Physical examination will also include an
examination of both hands to document whether any
finger joints are painful, swollen or tender [45,49]. In
addition, participants will be asked about visual impair-
ment (not corrected by glasses) at each visit and nearvisual acuity of each eye (with glasses where appropriate)
will be recorded using a standard reading chart at base-
line and 12 months [50].Medical history and demographic data
Medical history and demographic data, including smo-
king and alcohol consumption, employment and family
history of hand OA, will be recorded.Clinical parameters
Self-reported clinical outcomes, including pain and func-
tion, quality of life, anxiety and depression will be
assessed, as per Table 2.
Table 4 Dosing schedule
Male Female
Height Calculated
ideal body
weight
Dosage Height Calculated
ideal body
weight
Dosage
cm Feet cm Feet
<148 cm <4010″ <46 kg 200 mg daily <153 cm <500″ <46 kg 200 mg daily
≥148 cm and
<166 cm
≥4010″ and
<505″
≥46 and
<62 kg
Alternating doses of 200 mg
and 400 mg
≥153 and
<171 cm
≥500″ And
<507″
≥46 and
<62 kg
Alternating doses of 200 mg
and 400 mg
≥166 cm ≥505″ ≥62 kg 400 mg daily ≥171 cm ≥507″ ≥62 kg 400 mg daily
Summary of trial
PIL given and trial explained.
Participant given at least 24 h to decide whether 
they would like to enter the study
PIL given and 
study discussed
Screening visit
Informed consent gained
Bloods, pregnancy and visual acuity monitoring
Demographic and physical examination recorded
Participants meeting inclusion criteria recruited
Visit 1: Clinic
Screening 
- 3 weeks
Hydroxychloroquine group (Prescription 1)
200-400 mg (1 OR 2 capsules) daily for 12/12
Placebo group (Prescription 1)
1 OR 2 capsules daily for 12/12
Hand pain / global 0-10 scores / pain manikins / HADS / AUSCAN
Adverse events / concomitant meds
Prescription 2
Hand pain / global 0-10 scores / pain manikins
AUSCAN / OA QoL / HADS / EQ-5D / SF-12
Joint count / hand function / brief medication 
Adverse events / concomitant meds 
U&E / visual acuity / pregnancy dipstick
Bilateral hand X-rays
Follow-up as per routine NHS care
Visit 8: Clinic
12 months
Visit 4: Postal / 
telephone or clinic
3 months
Hand pain / global 0-10 scores / pain manikins
AUSCAN / OA QoL / HADS / EQ-5D / SF-12 
Joint count / hand function / brief medication
Adverse events / concomitant meds / U&E / visual acuity
Prescription 3
Visit 6: Clinic
6 months
Baseline visit
Randomisation / subject number assigned
Hand pain / global 0-10 scores / pain manikins
AUSCAN / OAQoL / HADS / EQ-5D / SF-12
Joint count / hand function tests
Bilateral hand X-rays / Ultrasound of one hand (6/9 centres)
Visit 2: Clinic
Baseline 
0 months
Visit 7: Telephone
9 months
Adverse events / concomitant meds
Prescription 4
Visit 3: Telephone
1 month Adverse events / concomitant meds
Telephone call
13 months Adverse events / concomitant meds
Figure 2 Summary of trial.
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http://www.trialsjournal.com/content/14/1/64Handgrip strength will be measured to the nearest
pound in both hands using a Jamar dynamometer [51].
Both hands will be alternately assessed in triplicate.
Medication compliance will be measured using the
brief medication questionnaire [52,53], and pharmacy
pill counts.Imaging assessments
Plain radiographs of each hand will be taken at baseline
and 12 months (one hand per film), [54]. A posteroanterior
(PA) view will be taken, where the palmar aspect of the
hand will be placed on the film with the fingers extended,
separated slightly and spaced evenly and with the entire
forearm placed flat against the X-ray table. A hand map will
be provided to each trial site to aid reproducibility of posi-
tioning [54] and to ensure consistency of hand positioning
between centres.
Radiographs will be scored using the Kallman scale,
which scores 24 joints (all but the metacarpophalangeal
joints) for six radiological features according to a semi-
numerical scale [44,55]. Radiographs will be scored by
two readers and the mean score for each feature and the
mean total score calculated for analysis.
Baseline ultrasound imaging will be performed for one
hand of all participants enrolled at the six centres partici-
pating in the substudy. All participants recruited at these
sites will have baseline ultrasound imaging of the most
painful (or dominant if both equally painful) hand. Each
joint will be scored for synovitis and osteophytes. Synovitis
will be graded using a semi-quantitative (0 to 3) score
using both greyscale (GS) and power Doppler (PD) moda-
lities. [56]. Abnormal PD will be defined as abnormal
blood flow located within the synovial hypertrophy; while
proliferation within the joint space osteophytes will be
scored as being present or absent and will be defined as a
‘step up’ or protrusion of cortical bone seen in more than
one plane [57].
Scoring will occur during the acquisition process; how-
ever, still images will be taken of all joints for 10 subjects.
These will be re-read by the same reader at the end of the
study to provide intra-reader reliability for each centre
and centrally to provide inter-reader reliability.Safety assessments
Adverse events will be recorded throughout the study.
Intensity and relationship to the study medication will
be ascribed.Blood and urine safety assessment
Safety of therapy will be assessed according to the Brit-
ish Society for Rheumatology (BSR) guidelines for
hydroxychloroquine [50]:1. Full blood count (FBC), liver function tests (LFT)
and urea, electrolytes (U&E) and creatinine tests will
be performed at screening; U&E tests will be
repeated at 6 and 12 months for all subjects over 60
or at risk of renal impairment.
2. Urine dipstick pregnancy test at baseline and 12
months for female participants with child-bearing
potential.
3. Rheumatoid factor and anti-cyclic citrullinated
peptide (CCP) will be measured at baseline.
Data integrity and management
All data obtained will be kept strictly confidential and
will be stored electronically on a database with secured
and restricted access. Datasets for each subject will be
identified by the participant trial identification number
only.
Withdrawal
Any participant who is unable to tolerate the treatment
must be withdrawn from the treatment. The participant
will continue to be followed up in the trial. A participant
can choose to withdraw from the trial at any time and
without giving a reason. However, if a reason is provided
this will be recorded. All data will be used up to the
point of withdrawal unless the withdrawing participant
withdraws consent for use of the data.
Trial site monitoring
The trial will be overseen and monitored by the York
Trials Unit on behalf of the Sponsor, the University of
Leeds. Each site will be assessed prior to site setup, and
visited again once the fifth participant is recruited or at
20 weeks after the start of recruitment at site, whichever
is sooner. The HERO trial was assessed as low-risk by
the Medicines and Healthcare Products Regulatory
Agency (MHRA), and therefore in addition to the single
monitoring visit, procedures for central monitoring at
the clinical trials unit have been put in place. This will
mainly involve cross-checking logs returned from the re-
search team and site pharmacy for consistency. A data
monitoring and ethics committee will provide indepen-
dent oversight to ensure data quality and compliance
with the trial protocol.
Study site staff training
A centralized introduction and training session was held
for all principal investigators and site staff. An ultraso-
nography training meeting was held separately at which
the ultrasound acquisition and scoring protocol was de-
veloped. In addition to this, a site initiation visit will be
held at all sites, in order to provide specific training to
all staff involved in the study ahead of recruitment.
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Despite the prevalence of hand OA, there is a distinct lack
of robust clinical effectiveness studies into nonsurgical in-
terventions for hand OA [58,59]. Randomized controlled
trials (RCTs) of hand OA to date have, in general, been
found to be of low quality, with a lack of consistent case
definition, a lack of standardized outcome measures and
inadequate powering, thereby limiting their interpretation
and generalizability to a clinical practice setting. The re-
cent EULAR evidence-based recommendations for the
management of hand OA [12], found a notable paucity of
clinical trials to guide recommendations for hand OA and
highlighted a pressing need for well-designed studies to
identify new treatment options.
We have proposed this protocol to determine whether
hydroxychloroquine may provide one such treatment op-
tion for people with hand OA. There has been growing
consensus over the past decade that synovitis plays an im-
portant role in the pathogenesis and symptoms of OA
[60-62]. This may be reflected in the anecdotal use of the
common anti-synovial RA therapies in OA, and the
EULAR Recommendations for Hand OA expert consen-
sus group highlighted the need to examine existing slow-
acting antirheumatic drugs (SAARDs) for their possible
symptomatic and structure-modifying effects in OA. The
HERO study therefore aims to examine these effects, as
well as to explore the importance of synovitis by including
a substudy using ultrasound. Ultrasonography provides
more sensitive detection of synovitis than clinical examin-
ation [18].
In summary, hand OA is an increasingly prevalent and
disabling condition in our ageing society and is already a
major cause of healthcare expenditure. Current treat-
ments for hand OA have major limitations and other an-
algesic treatments are needed. Synovitis is prevalent in
OA and previous studies have shown it to be associated
with pain in knee and hand OA. Hydroxychloroquine is
used in routine practice for treating synovitis in inflam-
matory arthritides such as RA, is used anecdotally as a
treatment for OA and has been shown to be effective at
reducing pain in pilot studies. Hydroxychloroquine has
an excellent safety profile, with toxicity generally associ-
ated with sustained periods of use that, owing to the nat-
ural history of hand OA, are unlikely to be an issue. We
propose that hydroxychloroquine will be a practical and
safe treatment to reduce synovitis and therefore reduce
pain in patients with moderate to severe OA hand symp-
toms. This will potentially provide a new treatment for
OA, which could be of particular use in the primary care
setting.Trial status
Recruitment and follow-up of participants is in progress.Abbreviations
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